AZD8421

PreclinicalSmall molecule

AstraZeneca

AZD8421 is one of 5 small molecule programs targeting ER+ HER2- Advanced Breast Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ER+ HER2- Advanced Breast CancerRecruiting

ER+ HER2- Advanced Breast CancerPreclinical

Recruiting

Competition

Competitive Landscape

4 competitors in ER+ HER2- Advanced Breast Cancer

#DrugCompanyPhaseTrials

Kisqali

Novartis

Preclinical

1 2

Ibrance

Pfizer

Preclinical

1 3

Verzenio

Eli Lilly

Preclinical

1 4

Camizestrant

AstraZeneca

Preclinical

1 5

AZD8421

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

ER+ HER2- Advanced Breast Cancer

NCT06188520

Clinical

Trials by Indication[1]

ER+ HER2- Advanced Breast Cancer1 trial

A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT06188520·564 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AZD8421. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD8421 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD8421. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AstraZeneca

AZD8421

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

ER+ HER2- Advanced Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News